Kymera Therapeutics ( (KYMR) ) has shared an update.
On March 3, 2025, Kymera Therapeutics’ Board and Compensation Committee approved the grant of performance stock units (PSUs) to key employees, including executives, under the company’s 2020 Stock Option and Incentive Plan. These PSUs will vest in three installments based on achieving specific clinical milestones, potentially impacting employee incentives and aligning them with the company’s clinical development goals.
More about Kymera Therapeutics
Kymera Therapeutics operates in the biopharmaceutical industry, focusing on the development of targeted protein degradation therapies. The company is known for its innovative approach to treating diseases by harnessing the body’s natural protein degradation mechanisms.
YTD Price Performance: -23.33%
Average Trading Volume: 537,983
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.04B
See more data about KYMR stock on TipRanks’ Stock Analysis page.